Gary brings together innovative technology from R&D partners with client projects to create synergies and novel readouts, improving assay quality and reducing client project SAR cycle times. Gary leverages over 30 years of pre-clinical drug discovery experience and a number of scientific papers in leading journals to aid the discovery of new chemical entities. Recent examples include the Promega Nanoluc© / NanoBRET© technology and it’s application in addition to Protein Simple high throughput Western blotting.
After gaining his Ph.D. from Edinburgh University in 1990, Gary joined Hoffmann La Roche (USA) to investigate retinoid pharmacology and the role of nuclear hormone receptors in foetal development. After five years he joined the Lead Generation Section of Glaxo (GSK - UK) in 1995, gaining expertise in the development of cell-based assays within the CNS disease area for high throughput screening as well as novel drug discovery assay technologies and automation. Upon leaving GSK, Gary spent over 10 years at AstraZeneca (UK), developing novel cell-culture robotics and evaluating and implementing new assay technologies for respiratory and inflammatory disease.
After leaving GSK, Gary spent over 10 years at AstraZeneca (UK), developing novel cell-culture robotics and evaluating and implementing new assay technologies for respiratory and inflammatory diseases, before founding Aurelia Bioscience. In 2011, Gary and Kathy Dodgson founded and established Aurelia Bioscience as a preclinical CRO in order to bring their expertise in technology to the biotechnology and pharma sectors. Aurelia BioScience was acquired by Charnwood Molecular in 2021, where Gary now leads the growth and strategic development of our Biology team as Senior Director of Biology.